Verastem, Inc.
About Verastem, Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $30.9M
- Net income
- -$209.5M
- Total assets
- $246.4M
- Market cap
- $326.0M
- Operating margin
- -550.3%
- Net margin
- -677.6%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $30.9M
- Operating expenses
- $201.0M
- Operating income
- -$170.1M
- Net income
- -$209.5M
- EPS (basic)
- $-3.02
- EPS (diluted)
- $-3.02
Balance sheet
- Total assets
- $246.4M
- Current assets
- $223.4M
- Total liabilities
- $189.2M
- Current liabilities
- $72.3M
- Shareholders’ equity
- $57.2M
Cash flow
- Operating cash flow
- -$137.5M
- Investing cash flow
- -$9.6M
- Financing cash flow
- $263.3M
- Net cash flow
- $116.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $326.0M
- EPS (diluted)
- $-3.02
- Shares outstanding
- 88.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jan 27, 2012
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $209.5M in FY2025.
- Revenue grew 1406% from FY2021 to FY2025.
- Trading 66% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Verastem, Inc..
Write a review
News about Verastem, Inc.
News & sentiment via Polygon.io
